New drug order may boost liver cancer fight
NCT ID NCT07285850
First seen Jan 04, 2026 · Last updated May 23, 2026 · Updated 17 times
Summary
This study compares two ways of giving the drugs bevacizumab and atezolizumab for advanced liver cancer that occurs with fatty liver disease. One group gets the drugs one after the other (sequential), the other gets them together (concurrent). The goal is to see which approach works better at shrinking tumors and extending life. About 20 adults with advanced liver cancer and fatty liver will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Eastern Hepatobiliary Surgery Hospital
RECRUITINGShanghai, Shanghai Municipality, 201805, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.